Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273

Stopped The landscape of the study area changed, making it impossible to continue the study.

Conditions

• Infectious Disease
• COVID-19

Interventions

• BIOLOGICAL: RVM-V001 10 µg
• BIOLOGICAL: RVM-V001 30 µg
• BIOLOGICAL: RVM-V001 60 µg

Sponsor

RVAC Medicines (US), Inc.